Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

被引:79
作者
Boucau, Julie [1 ]
Uddin, Rockib [2 ]
Marino, Caitlin [1 ]
Regan, James [3 ]
Flynn, James P. [3 ]
Choudhary, Manish C. [3 ,4 ]
Chen, Geoffrey [2 ]
Stuckwisch, Ashley M. [2 ]
Mathews, Josh [2 ]
Liew, May Y. [2 ]
Singh, Arshdeep [2 ]
Reynolds, Zahra [2 ]
Iyer, Surabhi L. [2 ]
Chamberlin, Grace C. [2 ]
Vyas, Tammy D. [2 ]
Vyas, Jatin M. [2 ,4 ]
Turbett, Sarah E. [2 ]
Li, Jonathan Z. [3 ,4 ]
Lemieux, Jacob E. [2 ,4 ,5 ]
Barczak, Amy K. [1 ,2 ,4 ]
Siedner, Mark J. [2 ,4 ]
机构
[1] Massachusetts Inst Technol MIT & Harvard, Massachusetts Gen Hosp MGH, Ragon Inst, Cambridge, MA USA
[2] Massachusetts Gen Hosp, Boston, MA 02215 USA
[3] Brigham & Womens Hosp, Boston, MA 02215 USA
[4] Harvard Med Sch, Boston, MA 02215 USA
[5] Broad Inst, Cambridge, MA 02138 USA
关键词
COVID-19; therapeutics; anti-virals; nirmatrelvir-ritonavir; virology;
D O I
10.1093/cid/ciac512
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log(10) copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.
引用
收藏
页码:E526 / E529
页数:4
相关论文
共 10 条
[1]  
[Anonymous], Fact Sheet for Healthcare Providers: Interpreting xMAP MultiFlexZika RNA Assay Test Results
[2]  
[Anonymous], Hospitalized adults: therapeutic management
[3]  
Boucau Julie, 2022, medRxiv, DOI 10.1101/2022.03.01.22271582
[4]  
Carlin A., 2022, VIROLOGIC IMMUNOLOGI, V2022, DOI DOI 10.21203/RS.3.RS-1662783/V1
[5]  
Charness M., 2022, RAPID RELAPSE SYMPTO, DOI [10.21203/rs.3.rs-1588371/v3, DOI 10.21203/RS.3.RS-1588371/V3]
[6]   SARS-CoV-2 viral load is associated with increased disease severity and mortality [J].
Fajnzylber, Jesse ;
Regan, James ;
Coxen, Kendyll ;
Corry, Heather ;
Wong, Colline ;
Rosenthal, Alexandra ;
Worrall, Daniel ;
Giguel, Francoise ;
Piechocka-Trocha, Alicja ;
Atyeo, Caroline ;
Fischinger, Stephanie ;
Chan, Andrew ;
Flaherty, Keith T. ;
Hall, Kathryn ;
Dougan, Michael ;
Ryan, Edward T. ;
Gillespie, Elizabeth ;
Chishti, Rida ;
Li, Yijia ;
Jilg, Nikolaus ;
Hanidziar, Dusan ;
Baron, Rebecca M. ;
Baden, Lindsey ;
Tsibris, Athe M. ;
Armstrong, Katrina A. ;
Kuritzkes, Daniel R. ;
Alter, Galit ;
Walker, Bruce D. ;
Yu, Xu ;
Li, Jonathan Z. .
NATURE COMMUNICATIONS, 2020, 11 (01)
[7]   Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 [J].
Hammond, Jennifer ;
Leister-Tebbe, Heidi ;
Gardner, Annie ;
Abreu, Paula ;
Bao, Weihang ;
Wisemandle, Wayne ;
Baniecki, MaryLynn ;
Hendrick, Victoria M. ;
Damle, Bharat ;
Simon-Campos, Abraham ;
Pypstra, Rienk ;
Rusnak, James M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (15) :1397-1408
[8]   Detection of the Omicron Variant Virus With the Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay [J].
Regan, James ;
Flynn, James P. ;
Choudhary, Manish C. ;
Uddin, Rockib ;
Lemieux, Jacob ;
Boucau, Julie ;
Bhattacharyya, Roby P. ;
Barczak, Amy K. ;
Li, Jonathan Z. ;
Siedner, Mark J. .
OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (03)
[9]  
Seaman Michael S, 2022, medRxiv, DOI 10.1101/2022.03.02.22271731
[10]   Duration of viral shedding and culture positivity with postvaccination SARS- CoV-2 delta variant infections [J].
Siedner, Mark J. ;
Boucau, Julie ;
Gilbert, Rebecca F. ;
Uddin, Rockib ;
Luu, Jonathan ;
Haneuse, Sebastien ;
Vyas, Tammy ;
Reynolds, Zahra ;
Iyer, Surabhi ;
Chamberlin, Grace C. ;
Goldstein, Robert H. ;
North, Crystal M. ;
Sacks, Chana A. ;
Regan, James ;
Flynn, James P. ;
Choudhary, Manish C. ;
Vyas, Jatin M. ;
Barczak, Amy K. ;
Lemieux, Jacob E. ;
Li, Jonathan Z. .
JCI INSIGHT, 2022, 7 (02)